Anti-rejection Drug May Increase Risk Of Diabetes After Kidney Transplant
Sunday, May 25, 2008 - 23:28
in Health & Medicine
For patients undergoing kidney transplantation, treatment with the anti-rejection drug sirolimus may lead to an increased risk of diabetes, reports a new study. The results suggested a higher rate of post-transplant diabetes among patients treated with sirolimus, compared to other anti-rejection drugs. Depending on which additional drugs they received, diabetes risk was 36 to 66 percent higher for patients receiving sirolimus.
Read the whole article on Science Daily
More from Science Daily
Related
- Anti-rejection drug may increase risk of diabetes after kidney transplantThu, 22 May 2008, 14:22:04 EDT
- Drug may prolong organ life in noncompliant kidney transplant patientsSat, 31 May 2008, 3:42:36 EDT
- Gene mutation increases drug toxicity, rejection risk in pediatric kidney transplantsWed, 18 Feb 2009, 9:56:22 EST
- Best post-transplant drug regimen identified for patients with new kidneysFri, 29 Jul 2011, 0:35:27 EDT
- Gene pattern may identify kidney transplant recipients who don't need life-long anti-rejection drugsMon, 24 May 2010, 17:36:19 EDT